Relmada Therapeutics, Inc. RLMD Excess tax benefits associated with employee equity plans (in percent)

Excess tax benefits associated with employee equity plans (in percent) at other companies

Virtu FinancialVIRT

0.1%-0.2pp

Q2 HoldingsQTWO

0.3%+0.1pp

PlexusPLXS

-2.1%-5.5pp

VestisVSTS

-3.8%-7.3pp

TFS FinancialTFSL

0.5%+0.1pp

Dave & Buster's EntertainmentPLAY

-0.3%-0.1pp

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Operating cash flow-$15.1M+16.6%

Market cap$677.17M+2,907%

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent.

The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Relmada Therapeutics, Inc.'s excess tax benefits associated with employee equity plans (in percent)?: Relmada Therapeutics, Inc. (RLMD) reported excess tax benefits associated with employee equity plans (in percent) of -15.5% in Q4 2025.
What does excess tax benefits associated with employee equity plans (in percent) mean?: This metric measures the percentage impact of excess tax benefits from share-based compensation on the overall effective tax rate. It indicates the degree to which equity-based compensation reduces the company's tax liability.